Luvesilocin

Last updated

Luvesilocin
Luvesilocin.svg
Clinical data
Other namesRE-104; RE104; FT-104; FT104; 4-Glutaryloxy-N,N-diisopropyltryptamine; 4-Hydroxy-N,N-diisopropyltryptamine O-glutarate; O-Glutaryl-4-hydroxy-N,N-diisopropyltryptamine; 4-HO-DiPT glutarate; O-Glutaryl-4-HO-DiPT; 4-GO-DiPT
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Elimination half-life 3–4 hours [1]
Identifiers
  • 1-[3-[2-[Bis(1-methylethyl)amino]ethyl]-1H-indol-4-yl] pentanedioate
CAS Number
PubChem CID
UNII
Chemical and physical data
Formula C21H30N2O
Molar mass 326.484 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O)C(C)C
  • InChI=1S/C21H30N2O4/c1-14(2)23(15(3)4)12-11-16-13-22-17-7-5-8-18(21(16)17)27-20(26)10-6-9-19(24)25/h5,7-8,13-15,22H,6,9-12H2,1-4H3,(H,24,25)
  • Key:LSDOIAGGRBGDJJ-UHFFFAOYSA-N

Luvesilocin (INN Tooltip International Nonproprietary Name), [2] also known by its developmental code names RE104 and FT-104, as well as by its chemical name 4-glutaryloxy-N,N-diisopropyltryptamine (4-HO-DiPT O-glutarate or 4-GO-DiPT), is an investigational drug product being developed by the pharmaceutical company Reunion Neuroscience. [3] Luvesilocin a prodrug ester of a synthetic psychedelic 4-hydroxytryptamine, 4-HO-DiPT. [4] It is one of a number of related psychedelic derivatives being developed as pharmaceuticals to treat mood disorders.

Contents

Luvesilocin is in human clinical trials as a possible treatment for postpartum depression and treatment-resistant depression. [5] [6] [7] [8] As of 2024, luvesilocin entered a Phase II clinical trial for post-partum depression. [9]

Pharmacology

Luvesilocin is a prodrug that is converted into the psychedelic tryptamine 4-HO-DiPT upon administration. [4] [10]  4-OH-DiPT is chemically related to the neurotransmitter serotonin and acts as a non-selective agonist of the serotonin receptors. 4-OH-DiPT acts as an agonist on the serotonin 2A receptor (Ki 120 nM). [4] Activation of one serotonin receptor, the serotonin 5-HT2A receptor, is specifically responsible for the hallucinogenic effects and preclinical behavioral changes induced by 4-OH-DiPT and other serotonergic psychedelics.

Research

Synthesis, pharmacology and preclinical studies with luvesilocin have been published. [4] 4-OH-DiPT, the active metabolite of luvesilocin, produces measurable head-twitch response in rodents, indicative of its psychedelic properties. [11] Discriminative stimulus tests in rats showed 4-OH-DiPT fully substituted for DOM with a 5-fold lower potency than DOM and 2-fold lower potency than psilocin. [12] Findings suggest that 4-OH-DiPT activates BLA interneurons via the 5-HT2A receptor to enhance GABAergic inhibition of BLA principal neurons in the basolateral amygdala, which provides a potential mechanism for suppressing learned fear (fear extinction). [13]

Luvesilocin is being developed as a subcutaneous injection. Luvesilocin has been investigated in a randomized, placebo-controlled, single escalating dose Phase 1 study in healthy volunteers to assess the safety of luvesilocin, as well as to characterize the pharmacodynamics, including the duration and intensity of the psychedelic experience. [14] The mean duration of the psychedelic experience after administration of RE104 30 mg in humans was found to be 3.7 hours. [1]

Luvesilocin is currently under investigation to treat postpartum depression (PPD). [1] [15] [16]

See also

References

  1. 1 2 3 Pollack M, Hocevar-Trnka J, Bryson N, Taylor B, Johnson M, Alexander R (December 2024). "ACNP 63rd Annual Meeting: Poster Abstracts P609-P914: P697. RE104: A Novel, Shorter-Acting Psychedelic for Post Partum Depression". Neuropsychopharmacology. 49 (Suppl 1): 418–594 (469–470). doi: 10.1038/s41386-024-02013-y . PMID   39643635.
  2. ↑ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl93.pdf [ bare URL PDF ]
  3. ↑ Braner S (May 8, 2024). "Reunion Neuroscience raises $103 million for a psychedelic to treat depression". Chemical & Engineering News .
  4. 1 2 3 4 Bryson N, Alexander R, Asnis-Alibozek A, Ehlers MD (June 2024). "RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine". ACS Chemical Neuroscience. 15 (12): 2386–2395. doi:10.1021/acschemneuro.4c00058. PMC   11191588 . PMID   38758589.
  5. ↑ Hallifax J (11 August 2022). "An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104".
  6. ↑ WO 2022/000091,Bryson N,"Tryptamine prodrugs",published 6 January 2022, assigned to Field Trip Psychedelics Inc.
  7. ↑ US 2022/0024956,Slassi A, Araujo J,"Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders.",published 27 January 2022, assigned to Mindset Pharma Inc.
  8. ↑ WO 2022/246572,Slassi A, Araujo J, Higgin GH, Gabriele J,"Hallucinogen-Fatty Acid Combination",published 1 December 2022, assigned to Mindset Pharma Inc.
  9. ↑ Alexander R, Hocevar-Trnka J (June 26, 2024). "RE104: A Novel, Fast-Acting Psychedelic for Postpartum Depression". psychiatrictimes.com.
  10. ↑ "Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of RE104 for Development in Depressive Disorders". GlobalNewswire. May 20, 2024 – via Yahoo!Finance.
  11. ↑ Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, et al. (April 2021). "Investigation of the Structure-Activity Relationships of Psilocybin Analogues". ACS Pharmacology & Translational Science. 4 (2): 533–542. doi:10.1021/acsptsci.0c00176. PMC   8033608 . PMID   33860183.
  12. ↑ Gatch MB, Hoch A, Carbonaro TM (April 2021). "Discriminative Stimulus Effects of Substituted Tryptamines in Rats". ACS Pharmacology & Translational Science. 4 (2): 467–471. doi:10.1021/acsptsci.0c00173. PMC   8033599 . PMID   33860176.
  13. ↑ Kelly TJ, Bonniwell EM, Mu L, Liu X, Hu Y, Friedman V, et al. (April 2024). "Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala". Neuropsychopharmacology. 49 (5): 854–863. doi:10.1038/s41386-023-01744-8. PMC   10948882 . PMID   37752222.
  14. ↑ "ANZCTR - Registration". www.anzctr.org.au. Retrieved 2025-03-26.
  15. ↑ Reunion Neuroscience Inc (2025-03-06). A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD) (Report). clinicaltrials.gov.
  16. ↑ Reunion Neuroscience Inc (2025-03-06). A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD) (Report). clinicaltrials.gov.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.